Rigel Pharmaceuticals Inc (RIGL) Noticias

Form 8-K - Current report

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual...

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS PR Newswire SOUTH SAN...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Rigel to Present at the Jefferies London Healthcare Conference

Rigel to Present at the Jefferies London Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Nov...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update

Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update PR Newswire SOUTH SAN...

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and...

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business...

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib) PR Newswire SOUTH SAN...